Vol. 4, Issue 10 (2015)

Author(s):
Tetyana Lenchuk, Sergiy Fedorov

Abstract:
Cardiac remodelling is central to the pathophysiology of heart failure (HF) and is an established prognostic factor in patients with HF. Left ventricular (LV) enlargement has been shown to be associated with an increased risk for adverse cardiac events, while reduced LV ejection fraction (LVEF) is a powerful predictor of cardiovascular outcomes and all-cause mortality. Patients were randomly allocated to ivabradine or placebo, superimposed on background therapy for HF. Complete echocardiographic data at baseline and 6 months were available for 180 patients with ischemic HF and sinus rhythm. Ivabradine is effective medicine for improving the main cardio-hemodynamic parameter in patients with ischemic heart failure.